OBJECTIVES This study sought to analyze health-related quality-of-life (HrQoL) outcomes of patients undergoing transcatheter aortic valve replacement (TAVR) based on data from GARY (German Aortic Valve Registry).
Detailed information on pre-, intra-, and postoperative characteristics, as well as 1-year outcomes, for both groups is given in Tables 1 to 4 . reported an increase in NYHA functional class compared to their pre-operative evaluation. Figure 2 shows the parallel NYHA functional class shift, from NYHA functional classes class III and IV to NYHA functional class I and II, in patients undergoing either TAVR-TV or TAVR-TA.
In line with NYHA functional class improvements, the VAS score also improved after 1 year. The VAS score increased significantly from 52.6% to 59.6% for the TAVR-TV group and from 55.8% to 58.5% for the TAVR-TA group at 1-year follow-up, respectively ( Figure 3 ). The VAS score difference between baseline and at 1 year was 7.01% for the TAVR-TV group and 2.75% for the TAVR-TA group. This difference in the improvement of the VAS score between both treatment modalities was statistically significant (p < 0.001) ( Figure 3 ).
EQ-5D-3L. The EQ-5D measures 5 quality-of-life dimensions each divided into 3 levels, ranging from no and mild complaints to severe complaints within individual dimensions. For the TAVR-TV group, the pre-operative values ranged from 33.4% to 64.8% for level 1 (no complaints), 31.5% to 63.4%
for level 2 (mild complaints), and 3.2% to 9.8% for level 3 (severe complaints) within the 5 dimensions.
Lange et al. For TAVR-TA, the pre-operative values were 35.5% to 74.6%, 21.8% to 58.5%, and 1.8% to 8.2% for levels 1, For the whole study population (independent of the access route) several independent risk factors dimensions questionnaire visual analog scale; other abbreviations as in Figure 1 . The HrQoL of patients, as determined using the EQ-5D assessment tool, significantly improved a year after TAVR when compared to baseline measurements. In parallel to the observed improvements in NYHA functional class, the VAS score, a measure of self-evaluated health status, also improved significantly for both TAVR-TA (þ2.7%) and TAVR-TV groups (þ7.0%). The magnitude of Percentage of patients in each of the 3 EQ-5D levels across each EQ-5D dimension at baseline and at 1 year for the TAVR-TV and TAVR-TA groups. Abbreviations as in Figure 1 .
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Health-Related Quality-of-Life After TAVR EQ-5D utilities increased by 0.08 to 0.10 at 6 and 12 months, with both TAVR and AVR, respectively, for the transfemoral cohort; for the TA cohort, the increase in EQ-5D scores was slightly less but nonetheless significant for both treatment modalities (14) .
The reduced HrQoL benefits for our TAVR-TA group might be partly explained by the fact that greater repeat hospital admissions were necessary for these patients. The results observed in our study are in contrast to a recent report published by Bona et al. (15) . In a prospective study including 264 consecutive patients receiving transfemoral or transapical TAVR, HrQoL was assessed using the EQ-5D questionnaire. The extent to which functional recovery following TAVR is affected by patient-and procedure-related Lange et al.
factors remains poorly understood and our ability to accurately identify patients who will most likely derive a benefit from TAVR (utility) is limited. In the context of the different studies investigating HrQoL after TAVR, both patient characteristics and procedural complications have been described to influence post-procedural recovery. However, predictive factors for the extent of HrQoL changes identified by available studies have been inconsistent. Goncalves et al. (19) showed that patients with peripheral vascular disease had less benefit in the extent of HrQoL improvement as shown by a lower enhancement in Minnesota Living With Heart Failure Questionnaire physical dimension score. Fairbairn et al. (12) showed that female sex and vascular complications were independent predictors of lower HrQoL periprocedural stroke were each associated with less substantial improvements in the SF-36 PCS. Stortecky et al. (22) observed that patients with preoperative chronic renal failure (defined as a serum creatinine >2.0 mg/dl) and obesity (defined as a BMI >30 kg/m 2 ), despite a significant improvement of HrQoL, had lower SF-36 PCS at follow-up if compared to patients without these comorbidities.
STUDY LIMITATIONS. Currently, the EQ-5D is the most well-known and commonly used generic measure of health status. However, the EQ-5D questionnaire has been criticized as a non-disease-specific instrument for HrQoL evaluation. Whilst in many applications the EQ-5D has been shown to be a valid and reliable measure of patient health, it has also been argued that in some contexts the 3-level version of the EQ-5D may lack sensitivity or fail to capture important aspects of health in certain disease areas (23) . As for now, specific HrQoL assessment tools for aortic stenosis do not exist. However, the EQ-5D was chosen because it is cognitively simple and takes only a few minutes to complete, both aspects being important in this elderly patient population. Moreover, the EQ-5D
has been widely employed as a generic HrQoL assessment tool in cardiovascular patients, involving populations affected by coronary artery disease, heart failure, or following heart transplantation (24-26).
However, HrQoL improvements seen in studies using other generic and disease-specific assessment tools appear more prominent and consistent than improvements measured by the EQ-5D (11).
Of the original study population, 2.6% was lost to follow-up. However, a lost-to-follow-up rate of <10%
is considered low and acceptable (11) . Given the typical high 1-year mortality within the study population of 23% (20.7% for the TAVR-TV group and 28.0% for the TAVR-TA group, respectively), the proportion of patients with available data diminished over time. As expected, and depicted in Online Abbreviations as in Tables 1, 3 , and 5.
Lange et al. WHAT IS NEW? To date, with a total of 2,288 included patients providing complete follow-up, the present study is the largest prospective nonrandomized series reporting on HrQoL outcomes in patients having undergone TAVR. HrQoL was prospectively measured using the EQ-5D-3L questionnaire at baseline and 1 year.
In parallel to improvements in NYHA functional class, TAVR was associated with HrQoL improvements after 1 year when compared to baseline, especially in terms of mobility and usual activities. The magnitude of improvements was higher in the TAVR-TV group as compared to the TAVR-TA group. However, there was a sizable group of patients who did not derive any HrQoL benefits. Several independent pre-and post-operative factors could be identified being predictive for less pronounced HrQoL benefits.
WHAT IS NEXT? HrQoL assessment should continue to be an important component of TAVR-related trials. The effect of newer generation devices, smaller and friendlier delivery systems, greater experience in appropriate patient selection and procedural performance on HrQoL outcomes, and the inclusion of lower-risk patients warrant future investigations.
